Cargando…

Complement activation during cardiopulmonary bypass and association with clinical outcomes

In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kefalogianni, Rengina, Kamani, Farah, Gaspar, Mihaela, Aw, TC, Donovan, Jackie, Laffan, Mike, Pickering, Matthew C., Arachchillage, Deepa J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175769/
https://www.ncbi.nlm.nih.gov/pubmed/35846208
http://dx.doi.org/10.1002/jha2.371
_version_ 1784722520484610048
author Kefalogianni, Rengina
Kamani, Farah
Gaspar, Mihaela
Aw, TC
Donovan, Jackie
Laffan, Mike
Pickering, Matthew C.
Arachchillage, Deepa J.
author_facet Kefalogianni, Rengina
Kamani, Farah
Gaspar, Mihaela
Aw, TC
Donovan, Jackie
Laffan, Mike
Pickering, Matthew C.
Arachchillage, Deepa J.
author_sort Kefalogianni, Rengina
collection PubMed
description In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantly immediately following the administration of UFH, C3a, C5a, Bb fragment and SC5b‐9 remained unchanged. During CPB, C3 and C4 continued to fall whilst both alternative and classical pathways activation markers, Bb, C3a, C5a and SC5b‐9 increased significantly. Protamine sulphate had no effect on classical pathway components or activation markers but decreased alternative pathway activation marker Bb. Over the 12–24 h post‐surgery, both classical and alternative pathway activation markers returned to baseline, whilst C3 and C4 levels increased significantly but not to baseline values. Total drain volume 24 h after the surgery showed a moderate inverse correlation with post‐protamine C3 (r = −0.46, p = 0.01) and C4 (r = −0.57, p = 0.0009) levels, whilst a moderate positive correlation was observed with post‐protamine C3a (r = 0.46, p = 0.009), C5a (r = 0.37, p = 0.04) and SC5b‐9 (r = 0.56, p = 0.001) levels but not with Bb fragment (r = 0.25, p = 0.17). Thus, inhibition of complement activation may be a therapeutic intervention to reduce post‐operative blood in patients undergoing CPB.
format Online
Article
Text
id pubmed-9175769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91757692022-07-14 Complement activation during cardiopulmonary bypass and association with clinical outcomes Kefalogianni, Rengina Kamani, Farah Gaspar, Mihaela Aw, TC Donovan, Jackie Laffan, Mike Pickering, Matthew C. Arachchillage, Deepa J. EJHaem Sickle Cell, Thrombosis, and Benign Haematology In this prospective, single‐centre observational study of 30 patients undergoing cardiopulmonary bypass (CPB), the effect of unfractionated heparin (UFH), CPB surgery and protamine sulphate on complement and on post‐operative blood loss were assessed. Although C3 and C4 levels decreased significantly immediately following the administration of UFH, C3a, C5a, Bb fragment and SC5b‐9 remained unchanged. During CPB, C3 and C4 continued to fall whilst both alternative and classical pathways activation markers, Bb, C3a, C5a and SC5b‐9 increased significantly. Protamine sulphate had no effect on classical pathway components or activation markers but decreased alternative pathway activation marker Bb. Over the 12–24 h post‐surgery, both classical and alternative pathway activation markers returned to baseline, whilst C3 and C4 levels increased significantly but not to baseline values. Total drain volume 24 h after the surgery showed a moderate inverse correlation with post‐protamine C3 (r = −0.46, p = 0.01) and C4 (r = −0.57, p = 0.0009) levels, whilst a moderate positive correlation was observed with post‐protamine C3a (r = 0.46, p = 0.009), C5a (r = 0.37, p = 0.04) and SC5b‐9 (r = 0.56, p = 0.001) levels but not with Bb fragment (r = 0.25, p = 0.17). Thus, inhibition of complement activation may be a therapeutic intervention to reduce post‐operative blood in patients undergoing CPB. John Wiley and Sons Inc. 2022-01-13 /pmc/articles/PMC9175769/ /pubmed/35846208 http://dx.doi.org/10.1002/jha2.371 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sickle Cell, Thrombosis, and Benign Haematology
Kefalogianni, Rengina
Kamani, Farah
Gaspar, Mihaela
Aw, TC
Donovan, Jackie
Laffan, Mike
Pickering, Matthew C.
Arachchillage, Deepa J.
Complement activation during cardiopulmonary bypass and association with clinical outcomes
title Complement activation during cardiopulmonary bypass and association with clinical outcomes
title_full Complement activation during cardiopulmonary bypass and association with clinical outcomes
title_fullStr Complement activation during cardiopulmonary bypass and association with clinical outcomes
title_full_unstemmed Complement activation during cardiopulmonary bypass and association with clinical outcomes
title_short Complement activation during cardiopulmonary bypass and association with clinical outcomes
title_sort complement activation during cardiopulmonary bypass and association with clinical outcomes
topic Sickle Cell, Thrombosis, and Benign Haematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175769/
https://www.ncbi.nlm.nih.gov/pubmed/35846208
http://dx.doi.org/10.1002/jha2.371
work_keys_str_mv AT kefalogiannirengina complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT kamanifarah complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT gasparmihaela complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT awtc complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT donovanjackie complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT laffanmike complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT pickeringmatthewc complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes
AT arachchillagedeepaj complementactivationduringcardiopulmonarybypassandassociationwithclinicaloutcomes